期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CAG方案治疗骨髓增生异常综合征疗效观察 被引量：2

原文传递
导出
摘要 目的观察CAG方案治疗骨髓增生异常综合征（MDS）疗效。方法经FAB标准确诊的MDS患者接受CAG方案（阿糖胞苷＋阿柔比星＋粒细胞集落刺激因子）诱导治疗。结果15例患者经过1个疗程后，10例骨髓获得完全缓解（CR），5例获得部分缓解（PR），PR者经两个疗程治疗后1例达CR，余改用其他方案治疗。结论CAG方案疗效较好，毒副作用相对较少，为MDS患者延长生存期、改善生活质量提供了一种可行的方案。
作者 陈亚峰 陈钰 王爱华 罗晓鸿 沈志祥
机构地区 上海市瑞金医院血液科 江西省新余市人民医院内一科进修医师
出处 《白血病．淋巴瘤》 CAS 2007年第1期54-55,共2页 Journal of Leukemia & Lymphoma
关键词 骨髓增生异常综合征 阿糖胞苷 阿柔比星 粒细胞集落刺激因子
分类号 R5 [医药卫生—内科学]
  • 相关文献

参考文献8

  • 1沈志祥主编..2002-血液病学新进展[M].北京:人民卫生出版社,2002:495.
  • 2张之南主编..血液病诊断及疗效标准 第2版[M].北京:科学出版社,1998:434.
  • 3Akashi K, Eto T, Shibuva T, et al. Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic symdrome cooperating with granulocyte colony-stimulating factor [J]. Leuk Res,2000, 24(3): 243-248. 被引量：1
  • 4Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms[J]. Blood,2002, 100(7): 2292-2302. 被引量：1
  • 5Bernasconi C, Alessandrino E P, Bernasconi P, et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodisplastic syndrome or secondary acute myeloid leukaemia evolving from MDS [J]. Br J Haematol, 1998, 102(3): 678-683. 被引量：1
  • 6Estey E H, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts intransformatio, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy[J]. Blood, 1997, 90(8): 2969-2977. 被引量：1
  • 7Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubiein in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation[J]. Int J Hematol, 2000, 71(3): 238-244. 被引量：1
  • 8Li J M, Shen Y, Wu D P, et al. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 chinese patients[J]. Int J Hematol, 2005, 82(1): 48-54. 被引量：1

同被引文献18

  • 1纪冬梅.CAG方案治疗未达完全缓解的初治急性髓系白血病的疗效观察[J].实用全科医学,2006,4(1):83-83. 被引量：3
  • 2De Witte T, Muus P, De Pauw B, et al. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia [ J ]. Cancer, 1990,66: 831-837. 被引量：1
  • 3Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysp lastic syndromes [ J ]. Blood,2000,96 : 3671-3674. 被引量：1
  • 4Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG forM yelofibrosis Research and Treatment ( IWG-MRT[ J ] ). Blood ,2006,108 : 1497-1503. 被引量：1
  • 5Saito K, Nakamaura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubcin in combination with granulocyte colony-stimulating factor( CAG regimen) for previously treated patients with replapsed or primary resistant acute myelogenous leukemia and previously untreated elderly patients with AML, secondary AML, and refractory anima with excess blastsin transformation [ J ]. Int J Hematol, 2000,71 ( 3 ) : 238 -244. 被引量：1
  • 6Lowenberg B, Van Putten W, Theobald M, et al. Effect of priming with granulocyte colony stimulating factor on the outcome of chemotherapy for acute myeloid leukemia[ J]. N Engl J Med,2003,349:743-752. 被引量：1
  • 7Cheson BD, Bennett JM, Kantarijian H, et al. Report of an international working group to standardize response criteria for myelodysp lastic syndromes[ J]. Blood .2000.96:3671 -3674. 被引量：1
  • 8Cai Z, Lin M, Wuchter C, et al. Apop totic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and imp licates Bax transIocation, mitochondrial cytoehrome c release and caspase activation [ J ]. Leukemia, 2001, 15(4) :567-574. 被引量：1
  • 9van de Loosdrecht A ,Wester TM,Westra AH ,et al.Idenification of distinct prognostic subgroups in low and intermediate-1 rick myelidysplastic syndromes by flow cytomery. Blood, 2008, 111:1067- 1077. 被引量：1
  • 10Vardeman JW. Hematopathological concepts and controveies in the diagnosis and ciagnosis and classigication of melidysplastic syndromes. Hmatology, 2006, ASH :199-204. 被引量：1

引证文献2

二级引证文献5

白血病．淋巴瘤
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部